Guerbet to Showcase its UNIK
Solution at RSNA 2020

NEWS PROVIDED BY
Guerbet LLC USA 
Nov 12, 2020, 18:00 ET

PRINCETON, N.J., Nov. 12, 2020 /PRNewswire/ -- Guerbet (GBT) a global leader in medical imaging,announced today that it will highlight UNIK, a tailored solution for diagnostic imaging, at the 2020
annual meeting of the Radiological Society of North America (RSNA).

UNIK is a exible solution designed to create value by re ecting healthcare professionals' speci c needs
and improvement areas. By understanding customers' internal processes, Guerbet can provide anecosystem of value by interconnecting its comprehensive portfolio of contrast media, injection solutions,digital solutions and technical support.

Key bene ts of UNIK include:-Traceability of the injected contrast media-Enhanced clinical operation through optimal product combination-

Potential cost savings, achieved through integration, improved work ow and smart nancing

services"We look forward to virtually engaging RSNA participants and sharing how our product portfolio, led byUNIK, provides bene ts for healthcare providers and their patients," said Thomas McLaughlin, VP,
Guerbet North America. "In today's virtual world we have created two ways for attendees to learn more,either through our RSNA virtual booth at www.rsna.org/annual-meeting or athttps://www.guerbet.com/en-us/rsna-2020/. Individual demonstrations may also be requested throughthe Guerbet site."/In addition to showcasing diagnostic and interventional solutions, Guerbet will host two informationalsessions:-An on-demand session entitled "Prostate Cancer: Where will AI bring value?" in theInnovation Theater. The number of pre-biopsy prostate MRIs has increased considerably in the last
decade, yielding a higher number of prostate volumes to analyze and limited number of prostateexpert radiologists. Presented by Dr. Joseph Stancanello, Director of MRI Research, Guerbet
Europe, the session will explore how arti cial intelligence can increase work ow productivity, raise
non-prostate-expert radiologists to the level of expert and share how Guerbet is addressing
challenges associated with prostate MRIs with its own dedicated AI research team.

-On Friday, December 4, from 2:00-2:30pm CT, Guerbet will host a "Highlights Demonstration"

at our virtual booth. The session will guide HCPs through Guerbet's digital solution offerings acrossthe patient experience to help close the loop with smart connectivity for monitoring andreporting. Products featured during the demonstration include:-Dose&Care®, a state-of-the-art digital solution to monitor patients' exposure to radiation-Contrast&Care®, a next-level contrast media injection data management solution enabling

imaging centers to collect, archive, examine and share data directly with Guerbet's injectors tohelp radiologists with patient care-IBM Watson Patient Synopsis, a radiologist-trained arti cial intelligence tool that extracts

relevant patient information and summarizes into a tailored and speci c dashboard to help
physicians make informed diagnostic decisions

Links to both virtual sessions will be available until April 2021. To learn more, visit Guerbet atwww.rsna.org/annual-meeting or https://www.guerbet.com/en-us/rsna-2020/.

About Guerbet
Guerbet is a leader in medical imaging worldwide, offering a wide range of pharmaceutical products,
medical devices, digital and AI solutions for diagnostic and interventional imaging, to improve thediagnosis and treatment of patients. A pioneer since more than 90 years in the eld of contrast media
with over 2,800 people globally, Guerbet is continuously innovating with 9% of revenue dedicated to
Research & Development and four centers in France, Israel and the United States. Guerbet (GBT) is listed
on Euronext Paris (segment B – mid caps) and generated €817 million in revenue in 2019. For more
information about Guerbet, please visit www.guerbet.com.
/

SOURCE Guerbet LLC USARelated Links
http://www.guerbet.com/